New research shows simufilam suppresses overactive mtor

Austin, texas, june 27, 2023 (globe newswire) -- cassava sciences, inc. (nasdaq: sava), a clinical-stage biotechnology company, today announced the publication of a new paper in frontiers in aging, a peer-reviewed journal focused on age-related scientific research. the new paper examined the effects of simufilam on mtor. simufilam is cassava sciences' novel, oral drug candidate currently in phase 3 clinical testing in patients with mild-to-moderate alzheimer's disease dementia.
SAVA Ratings Summary
SAVA Quant Ranking